We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Another Possible Blockbuster Drug for Gilead Approved by FDA

Another Possible Blockbuster Drug for Gilead Approved by FDA

July 28, 2014

The FDA has cleared Gilead’s new treatment for three types of rare blood cancers, potentially creating another blockbuster drug for manufacturer of the hepatitis C treatment Sovaldi.

Approved under the agency’s breakthrough therapy designation pathway, Zydelig (idelalisib) is indicated for use in combination with Genentech’s Rituxan (rituximab) to treat patients whose chronic lymphotic leukemia (CLL) has returned.

The drug also received accelerated approval to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma, the FDA said. For those indications, Zydelig is intended to be used in patients who have received at least two prior systemic therapies, the agency added.

The CLL indication was approved based on results from a 220-patient clinical trial, which was stopped early because participants treated with the combination lived 10.7 months without their disease progressing compared with 5.5 months for the placebo and Rituxan group, the agency said.

The two other indications were approved based on a 123-patient trial that showed a 54 percent response rate for patients with released follicular B-cell non-Hodgkin lymphoma and 58 percent for relapsed small lymphocytic lymphoma.

Zydelig has the potential to be very profitable for Gilead, according to an EvaluatePharma analysis. The research firm projects Zydelig will generate $151 million in sales in 2015 and up to $1.2 billion in annual sales by 2020.

Zydelig is the seventh drug to win approval under the FDA’s breakthrough therapy designation pathway, which was created in 2012 for drugs that treat serious and life-threatening conditions and offer a substantial improvement over existing therapies. Drugs in the pathway receive faster reviews. — Robert King

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing